摘要
目的:探讨不同剂量瑞舒伐他汀对急性动脉硬化脑梗死(ACI)病人外周血淋巴细胞OX40L及血清OX40L和hs-CRP水平的影响。方法:选择40名动脉硬化性脑梗死病人,随机分为瑞舒伐他汀20 mg治疗组(A组)和瑞舒伐他汀10 mg治疗组(B组),应用QRT-PCR及酶联免疫吸附试验(ELISA)法分别检测外周血淋巴细胞OX40L及血清OX40L和hs-CRP的水平。结果:A组与B组外周血淋巴细胞OX40L下降幅度比较(P<0.01)及血清sOX40L和CRP水平治疗后有明显降低(P<0.05),A组与B组比较A组降低更加明显,有统计学意义。结论:动脉硬化性脑梗死病人急性期服用瑞舒伐他汀20 mg能更明显的降低患者外周血淋巴细胞OX40L及血清OX40L和CRP的水平,提示动脉粥样硬化性脑梗死病人早期服用较大剂量的他汀药物治疗效果可能更好。
Objective： To observe the effect of early Ruishufatadin therapy in different dosages on the expression of OX40L in human peripheral blood lymphocytes （PBL）and serum levels of soluble OX40L, hs-CRP in patients with ACI. Methods： Patients with atherosclerotic cerebral infarction were treated with Ruishufatadin20mg/day and 10mg/day for 7 days. PBLs were isolated, and the effects of Ruishufatadin on OX40L expression were evaluated by QRT-PCR. Serum sOX40L, hs-CRP examined with ELISA at baseline and after therapy. Results： Our data shown that 1. The OX40LmRNA of Human PBLs was decreased in both A and B group. A group is lower （P 〈 0.01）. 2. The concentration of sOX40L and hs-CRP after the Ruishufatadin intervene were decreased in both A and B group. Levels of serum OX40L and hs-CRP in A group are lower （P 〈0.05）. Conclusions： On clinical, our data suggest Ruishufatadine has a much more significant decrease of OX40L and sOX40L, hs-CRP at 20mg/d than at 10mg/d on ACI patients. Therefore we suggest that all patients with ACI should take Ruishufatadin at larger dosage as early as possible.
出处
《现代生物医学进展》
CAS
2013年第20期3900-3903,共4页
Progress in Modern Biomedicine
基金
黑龙江省科技攻关资助项目(GC10C305-2)
黑龙江省自然科学基金(批准号:D201167()2012-2014)
